Clinical and Experimental Vaccine Research

  • 제12권4호
  • /
  • Pages.265-290
  • /
  • 2023
  • /
  • 2287-3651(pISSN)
  • /
  • 2287-366X(eISSN)
대한백신학회 (The Korean Vaccine Society)
권호 표지
DOI QR코드

DOI QR Code

COVID-19 vaccine-induced immune thrombotic thrombocytopenia: a review

  • Siti Nur Atikah Aishah Suhaimi (Department of Pharmacy Practice, Universiti Teknologi MARA Selangor Branch) ;
  • Izzati Abdul Halim Zaki (Department of Pharmacy Practice, Universiti Teknologi MARA Selangor Branch) ;
  • Zakiah Mohd Noordin (Department of Pharmacy Practice, Universiti Teknologi MARA Selangor Branch) ;
  • Nur Sabiha Md Hussin (Department of Pharmacy Practice, Universiti Teknologi MARA Selangor Branch) ;
  • Long Chiau Ming (School of Medical and Life Sciences, Sunway University) ;
  • Hanis Hanum Zulkifly (Department of Pharmacy Practice, Universiti Teknologi MARA Selangor Branch)
  • 투고 : 2023.01.19
  • 심사 : 2023.10.17
  • 발행 : 2023.10.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Rare but serious thrombotic incidents in relation to thrombocytopenia, termed vaccine-induced immune thrombotic thrombocytopenia (VITT), have been observed since the vaccine rollout, particularly among replication-defective adenoviral vector-based severe acute respiratory syndrome coronavirus 2 vaccine recipients. Herein, we comprehensively reviewed and summarized reported studies of VITT following the coronavirus disease 2019 (COVID-19) vaccination to determine its prevalence, clinical characteristics, as well as its management. A literature search up to October 1, 2021 using PubMed and SCOPUS identified a combined total of 720 articles. Following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guideline, after screening the titles and abstracts based on the eligibility criteria, the remaining 47 full-text articles were assessed for eligibility and 29 studies were included. Findings revealed that VITT cases are strongly related to viral vector-based vaccines, which are the AstraZeneca COVID-19 vaccine (95%) and the Janssen COVID-19 vaccine (4%), with much rarer reports involving messenger RNA-based vaccines such as the Moderna COVID-19 vaccine (0.2%) and the Pfizer COVID-19 vaccine (0.2%). The most severe manifestation of VITT is cerebral venous sinus thrombosis with 317 cases (70.4%) and the earliest primary symptom in the majority of cases is headache. Intravenous immunoglobulin and non-heparin anticoagulant are the main therapeutic options for managing immune responses and thrombosis, respectively. As there is emerging knowledge on and refinement of the published guidelines regarding VITT, this review may assist the medical communities in early VITT recognition, understanding the clinical presentations, diagnostic criteria as well as its management, offering a window of opportunity to VITT patients. Further larger sample size trials could further elucidate the link and safety profile.

키워드

참고문헌

  1. Sharifian-Dorche M, Bahmanyar M, Sharifian-Dorche A, Mohammadi P, Nomovi M, Mowla A. Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis post COVID-19 vaccination; a systematic review. J Neurol Sci 2021;428:117607.
  2. Swan D, Enright H, Desmond R, et al. Vaccine-induced thrombosis and thrombocytopenia (VITT) in Ireland: a review of cases and current practices. Thromb Update 2021;5:100086.
  3. Medicines and Healthcare products Regulatory Agency. Coronavirus vaccine: summary of Yellow card reporting [Internet]. London: Medicines and Healthcare products Regulatory Agency; 2021 [cited 2023 Jan 10]. Available from: https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting
  4. Centers for Disease Control and Prevention. Johnson & Johnson/Janssen COVID-19 vaccine and thrombosis with thrombocytopenia syndrome (TTS): update for clinicians [Internet]. Atlanta (GA): Centers for Disease Control and Prevention; 2021 [cited 2023 Jan 10]. Available from: https://emergency.cdc.gov/coca/ppt/2021/COCA-Call-4-27-2021-final.pdf
  5. Cheng D, Machingaifa F, Buntsma D, McGuire R. Thrombosis with thrombocytopenia syndrome (TTS) [Internet]. Melbourne (VIC): Vaccine Education Centre; 2021 [cited 2023 Jan 10]. Available from: https://mvec.mcri.edu.au/references/thrombosis-with-thrombocytopenia-syndrome/
  6. Schultz NH, Sorvoll IH, Michelsen AE, et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med 2021;384:2124-30.
  7. Scully M, Singh D, Lown R, et al. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. N Engl J Med 2021;384:2202-11.
  8. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med 2021;384:2092-101.
  9. Blauenfeldt RA, Kristensen SR, Ernstsen SL, Kristensen CC, Simonsen CZ, Hvas AM. Thrombocytopenia with acute ischemic stroke and bleeding in a patient newly vaccinated with an adenoviral vector-based COVID-19 vaccine. J Thromb Haemost 2021;19:1771-5.
  10. Pavord S, Scully M, Hunt BJ, et al. Clinical features of vaccine-induced immune thrombocytopenia and thrombosis. N Engl J Med 2021;385:1680-9.
  11. Al-Mayhani T, Saber S, Stubbs MJ, et al. Ischaemic stroke as a presenting feature of ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia. J Neurol Neurosurg Psychiatry 2021;92:1247-8.
  12. American Society of Hematology. Thrombosis with thrombocytopenia syndrome: vaccine-induced thrombotic thrombocytopenia [Internet]. Washington (DC): American Society of Hematology; 2022 [cited 2023 Jan 10]. Available from: https://www.hematology.org/covid-19/vaccine-induced-immune-thrombotic-thrombocytopenia
  13. International Society on Thrombosis and Haemostasis. The ISTH releases interim guidance on vaccine-induced immune thrombotic thrombocytopenia (VITT) [Internet]. Carrboro (NC): International Society on Thrombosis and Haemostasis; 2021 [cited 2023 Jan 10]. Available from: https://www.isth.org/news/561406/The-ISTH-ReleasesInterim-Guidance-on-Vaccine-Induced-Immune-Thrombotic-Thrombocytopenia-VITT-.htm
  14. British Society for Haematology. Guidance produced by the expert haematology Panel (EHP) focussed on vaccine induced thrombosis and thrombocytopenia (VITT) [Internet]. London: British Society for Haematology; 2021 [cited 2023 Jan 10]. Available from: https://b-s-h.org.uk/about-us/news/guidance-produced-by-the-expert-haematology-panel-ehp-focussed-on-vaccine-induced-thrombosis-and-thrombocytopenia-vitt/
  15. Oldenburg J, Klamroth R, Langer F, et al. Diagnosis and management of vaccine-related thrombosis following AstraZeneca COVID-19 vaccination: guidance statement from the GTH. Hamostaseologie 2021;41:184-9.
  16. Symptoms of thrombosis and their diagnostic evaluation in VITT (vaccine-induced immune thrombotic thrombocytopenia) [Internet]. Waltham (MA): UpToDate; 2021 [cited 2023 Jan 10]. Available from: https://www.uptodate.com/contents/image?imageKey=HEME%2F131492&topicKey=HEME%2F131333&source=see_link
  17. International Society on Thrombosis and Haemostasis. ISTH Interim Guidance for the Diagnosis and Treatment on Vaccine-Induced Immune Thrombotic Thrombocytopenia [Internet]. Carrboro (NC): International Society on Thrombosis and Haemostasis; 2021 [cited 2023 Jan 10]. Available from: https://cdn.ymaws.com/www.isth.org/resource/resmgr/ISTH_VITT_Guidance_2.pdf
  18. Thrombosis and Haemostasis Society of Australia and New Zealand. Suspected vaccine induced immune thrombotic thrombocytopenia (VITT) [Internet]. Brunswick West (VIC): Thrombosis and Haemostasis Society of Australia and New Zealand; 2021 [cited 2023 Jan 10]. Available from: https://www.thanz.org.au/documents/item/591
  19. Pai M, Chan B, Stall NM, et al. Vaccine-induced immune thrombotic thrombocytopenia (VITT) following adenovirus vector COVID-19 vaccination [Internet]. Toronto (ON): Ontario COVID-19 Science Advisory Table; 2021 [cited 2023 Jan 10]. Available from: https://covid19-sciencetable.ca/sciencebrief/vaccine-induced-immunethrombotic-thrombocytopenia-vitt-following-adenovirus-vector-covid-19-vaccination/
  20. Furie KL, Cushman M, Elkind MS, Lyden PD, Saposnik G; American Heart Association/American Stroke Association Stroke Council Leadership. Diagnosis and management of cerebral venous sinus thrombosis with vaccine-induced immune thrombotic thrombocytopenia. Stroke 2021;52:2478-82.
  21. Pavord S, Lester W, Makris M, Scully M, Hunt B. Guidance from the Expert Haematology Panel (EHP) on Covid-19 vaccine-induced immune thrombocytopenia and thrombosis (VITT) [Internet]. London: British Society for Haematology; 2021 [cited 2023 Jan 10]. Available from: https://b-s-h.org.uk/media/19590/guidance-version-17-on-mngmt-of-vitt-20210420.pdf
  22. Aladdin Y, Algahtani H, Shirah B. Vaccine-induced immunethrombotic thrombocytopenia with disseminated intravascular coagulation and death following the ChAdOx1 nCoV-19 vaccine. J Stroke Cerebrovasc Dis 2021;30:105938.
  23. Bano F, Badugama B, Chandra D. Thrombosis and thrombocytopaenia after ChAdOx1 nCoV-19 vaccination: a single UK centre experience. BMJ Case Rep 2021;14:e243894.
  24. Bjornstad-Tuveng TH, Rudjord A, Anker P. Fatal cerebral haemorrhage after COVID-19 vaccine. Tidsskr Nor Laegeforen 2021 Apr 29 [Epub]. https://doi.org/10.4045/tidsskr.21.0312
  25. Castelli GP, Pognani C, Sozzi C, Franchini M, Vivona L. Cerebral venous sinus thrombosis associated with thrombocytopenia post-vaccination for COVID-19. Crit Care 2021;25:137.
  26. Clark RT, Johnson L, Billotti J, et al. Early outcomes of bivalirudin therapy for thrombotic thrombocytopenia and cerebral venous sinus thrombosis after Ad26.COV2.S vaccination. Ann Emerg Med 2021;78:511-4.
  27. D'Agostino V, Caranci F, Negro A, et al. A rare case of cerebral venous thrombosis and disseminated intravascular coagulation temporally associated to the COVID-19 vaccine administration. J Pers Med 2021;11:285.
  28. Franchini M, Testa S, Pezzo M, et al. Cerebral venous thrombosis and thrombocytopenia post-COVID-19 vaccination. Thromb Res 2021;202:182-3.
  29. Guan CY, Tsai SH, Fan JS, Lin YK, Kao CC. Middle-age Asian male with cerebral venous thrombosis after COVID-19 AstraZeneca vaccination. Am J Emerg Med 2022;51:427.
  30. Guetl K, Gary T, Raggam RB, Schmid J, Wolfler A, Brodmann M. SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia treated with immunoglobulin and argatroban. Lancet 2021;397:e19.
  31. Kennedy VE, Wong CC, Hong JM, et al. VITT following Ad26. COV2.S vaccination presenting without radiographically demonstrable thrombosis. Blood Adv 2021;5:4662-5.
  32. Malik B, Kalantary A, Rikabi K, Kunadi A. Pulmonary embolism, transient ischaemic attack and thrombocytopenia after the Johnson & Johnson COVID-19 vaccine. BMJ Case Rep 2021;14:e243975.
  33. Mehta PR, Apap Mangion S, Benger M, et al. Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19 vaccination: a report of two UK cases. Brain Behav Immun 2021;95:514-7.
  34. Muir KL, Kallam A, Koepsell SA, Gundabolu K. Thrombotic thrombocytopenia after Ad26.COV2.S vaccination. N Engl J Med 2021;384:1964-5.
  35. Ramdeny S, Lang A, Al-Izzi S, Hung A, Anwar I, Kumar P. Management of a patient with a rare congenital limb malformation syndrome after SARS-CoV-2 vaccine-induced thrombosis and thrombocytopenia (VITT). Br J Haematol 2021;195:299.
  36. Rodriguez EV, Bouazza FZ, Dauby N, et al. Fatal vaccine-induced immune thrombotic thrombocytopenia (VITT) post Ad26.COV2.S: first documented case outside US. Infection 2022;50:531-6.
  37. Sangli S, Virani A, Cheronis N, et al. Thrombosis with thrombocytopenia after the messenger RNA-1273 vaccine. Ann Intern Med 2021;174:1480-2.
  38. See I, Su JR, Lale A, et al. US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26. COV2.S vaccination, March 2 to April 21, 2021. JAMA 2021;325:2448-56.
  39. Suresh P, Petchey W. ChAdOx1 nCOV-19 vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis (CVST). BMJ Case Rep 2021;14:e243931.
  40. Tolboll Sorensen AL, Rolland M, Hartmann J, et al. A case of thrombocytopenia and multiple thromboses after vaccination with ChAdOx1 nCoV-19 against SARS-CoV-2. Blood Adv 2021;5:2569-74.
  41. Xie C, Vincent L, Chadwick A, Peschl H. COVID-19 vaccine induced prothrombotic immune thrombocytopenia. Eur Heart J 2021;42:3206.
  42. Perry RJ, Tamborska A, Singh B, et al. Cerebral venous thrombosis after vaccination against COVID-19 in the UK: a multicentre cohort study. Lancet 2021;398:1147-56.
  43. Sanchez van Kammen M, Aguiar de Sousa D, Poli S, et al. Characteristics and Outcomes of patients with cerebral venous sinus thrombosis in SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia. JAMA Neurol 2021;78:1314-23.
  44. Tiede A, Sachs UJ, Czwalinna A, et al. Prothrombotic immune thrombocytopenia after COVID-19 vaccination. Blood 2021;138:350-3.
  45. Wolf ME, Luz B, Niehaus L, Bhogal P, Bazner H, Henkes H. Thrombocytopenia and intracranial venous sinus thrombosis after "COVID-19 vaccine AstraZeneca" exposure. J Clin Med 2021;10:1599.
  46. Tsilingiris D, Vallianou NG, Karampela I, Dalamaga M. Vaccine induced thrombotic thrombocytopenia: the shady chapter of a success story. Metabol Open 2021;11:100101.
  47. McGonagle D, De Marco G, Bridgewood C. Mechanisms of immunothrombosis in vaccine-induced thrombotic thrombocytopenia (VITT) compared to natural SARS-CoV-2 infection. J Autoimmun 2021;121:102662.
  48. Greinacher A, Selleng K, Palankar R, et al. Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia. Blood 2021;138:2256-68.
  49. Iba T, Levy JH. The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune thrombotic thrombocytopenia. Trends Cardiovasc Med 2022;32:1-9.
  50. Ruggeri ZM, Ruf W. Is VITT really a HIT. Nat Immunol 2021;22:1352-3.
  51. Cines DB, Bussel JB. SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia. N Engl J Med 2021;384:2254-6.
  52. What is venous thromboembolism? [Internet]. Bethesda (MD): National Institutes of Health (NIH); 2022 [cited 2023 Jan 10]. Available from: https://www.nhlbi.nih.gov/health/venous-thromboembolism
  53. Fields JM, Dean AJ. DVT, limited compression ultrasonography. In: Vincent JL, Hall JB, editors. Encyclopedia of intensive care medicine. Berlin: Springer; 2012. p. 769-75.
  54. Kabashneh S, Singh V, Alkassis S. A comprehensive literature review on the management of distal deep vein thrombosis. Cureus 2020;12:e8048.
  55. Ouellette DR, Harrington A, Kamangar N. Pulmonary embolism (PE) [Internet]. New York (NY): Medscape; 2020 [cited 2023 Jan 10]. Available from: https://emedicine.medscape.com/article/300901-overview
  56. Pongmoragot J, Saposnik G. Intracerebral hemorrhage from cerebral venous thrombosis. Curr Atheroscler Rep 2012;14:382-9.
  57. Tadi P, Behgam B, Baruffi S. Cerebral venous thrombosis. Treasure Island (FL): StatPearls Publishing; 2023.
  58. Humbert K, Favilla CG. Cerebral venous sinus thrombosis. In: Cucchiara BL, Price RS, editors. Decision-making in adult neurology. Philadelphia (PA): Elsevier; 2021. p. 118-9.
  59. Expert Haematology Panel. Letter to MHRA from Expert Haematology Panel group and endorsed by Thrombosis UK [Internet]. London: British Society for Haematology; 2021 [cited 2023 Jan 10]. Available from: https://b-s-h.org.uk/media/19537/letter-to-mhra-from-expert-haematology-group-endorsed-by-thrombosis-uk-1300-8th-april-2021.pdf
  60. Public Health Agency. Blood clotting following COVID-19 vaccination [Internet]. Belfast: Public Health Agency; 2021 [cited 2023 Jan 10]. Available from: https://www.publichealth.hscni.net/sites/default/files/2021-07/COVID-19_V4_AZ_factsheet_9pp_A4_11_07_21_final.pdf
  61. Updated Proposed Brighton Collaboration process for developing a standard case definition for study of new clinical syndrome X, as applied to Thrombosis with thrombocytopenia syndrome (TTS) [Internet]. Decatur (GA): Brighton Collaboration; 2021 [cited 2023 Jan 10]. Available from: https://brightoncollaboration.us/thrombosis-with-thrombocytopenia-syndrome-interim/
  62. Bussel JB, Connors JM, Cines DB, et al. Thrombosis with thrombocytopenia syndrome: vaccine-induced immune thrombotic thrombocytopenia [Internet]. Washington (DC): American Society of Hematology; 2021 [cited 2023 Jan 10]. Available from: https://www.hematology.org/covid-19/vaccine-induced-immune-thrombotic-thrombocytopenia
  63. Favaloro EJ, Pasalic L, Lippi G. Review and evolution of guidelines for diagnosis of COVID-19 vaccine induced thrombotic thrombocytopenia (VITT). Clin Chem Lab Med 2021;60:7-17.
  64. Favaloro EJ. Laboratory testing for suspected COVID-19 vaccine-induced (immune) thrombotic thrombocytopenia. Int J Lab Hematol 2021;43:559-570.
  65. Warkentin TE, Cuker A. COVID-19: vaccine-induced immune thrombotic thrombocytopenia (VITT) [Internet]. Waltham (MA): UpToDate; 2023 [cited 2023 Jan 10]. Available from: https://www.uptodate.com/contents/covid-19-vaccine-induced-immune-thrombotic-thrombocytopenia-vitt#H3576070944
  66. National Institute for Health and Care Excellence. COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis (VITT) [Internet]. London: National Institute for Health and Care Excellence; 2021 [cited 2023 Jan 10]. Available from: https://www.nice.org.uk/guidance/ng200/resources/covid19-rapid-guidelinevaccineinduced-immune-thrombocytopenia-and-thrombosis-vitt-pdf-51036811744
  67. Platton S, Bartlett A, MacCallum P, et al. Evaluation of laboratory assays for anti-platelet factor 4 antibodies after ChAdOx1 nCOV-19 vaccination. J Thromb Haemost 2021;19:2007-13.
  68. Greinacher A, Langer F, Makris M, et al. Vaccine-induced immune thrombotic thrombocytopenia (VITT): update on diagnosis and management considering different resources. J Thromb Haemost 2022;20:149-56.
  69. Akhondi H, Ganjali S, Nagalli S. Splanchnic venous thrombosis. Treasure Island (FL): StatPearls Publishing; 2023.
  70. Heijboer H, Buller HR, Lensing AW, Turpie AG, Colly LP, ten Cate JW. A comparison of real-time compression ultrasonography with impedance plethysmography for the diagnosis of deep-vein thrombosis in symptomatic outpatients. N Engl J Med 1993;329:1365-9.
  71. Lensing AW, Prandoni P, Brandjes D, et al. Detection of deep-vein thrombosis by real-time B-mode ultrasonography. N Engl J Med 1989;320:342-5.
  72. Swanson E. Doppler ultrasound imaging for detection of deep vein thrombosis in plastic surgery outpatients: a prospective controlled study. Aesthet Surg J 2015;35:204-14.
  73. Perrier A. Noninvasive diagnosis of pulmonary embolism. Haematologica 1997;82:328-31.
  74. Moore AJ, Wachsmann J, Chamarthy MR, Panjikaran L, Tanabe Y, Rajiah P. Imaging of acute pulmonary embolism: an update. Cardiovasc Diagn Ther 2018;8:225-43.
  75. Dogan H, de Roos A, Geleijins J, Huisman MV, Kroft LJ. The role of computed tomography in the diagnosis of acute and chronic pulmonary embolism. Diagn Interv Radiol 2015;21:307-16.
  76. Kjaergaard J, Schaadt BK, Lund JO, Hassager C. Quantification of right ventricular function in acute pulmonary embolism: relation to extent of pulmonary perfusion defects. Eur J Echocardiogr 2008;9:641-5.
  77. Pluta RM, Lynm C, Golub RM. JAMA patient page. Stroke imaging. JAMA 2011;306:1277.
  78. MRI more sensitive than CT in diagnosing stroke. Emerg Med News 2007;29:29.
  79. Rizk JG, Gupta A, Sardar P, et al. Clinical characteristics and pharmacological management of COVID-19 vaccine-induced immune thrombotic thrombocytopenia with cerebral venous sinus thrombosis: a review. JAMA Cardiol 2021;6:1451-60.
  80. Makris M, Pavord S, Lester W, Scully M, Hunt B. Vaccine-induced immune thrombocytopenia and thrombosis (VITT). Res Pract Thromb Haemost 2021;5:e12529.
  81. Gessler F, Schmitz AK, Dubinski D, et al. Neurosurgical considerations regarding decompressive craniectomy for intracerebral hemorrhage after SARS-CoV-2-vaccination in vaccine induced thrombotic thrombocytopenia-VITT. J Clin Med 2021;10:2777.
  82. Thomas S, Makris M. The reversal of anticoagulation in clinical practice. Clin Med (Lond) 2018;18:314-9.
  83. Kuramatsu JB, Sembill JA, Gerner ST, et al. Management of therapeutic anticoagulation in patients with intracerebral haemorrhage and mechanical heart valves. Eur Heart J 2018;39:1709-23.